Metraipolis › archive › dc_8d12e048d1ea

Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis:… — Europe PMC PMID:41973991

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41973991
DOI: 10.1093/annalsats/aaoag021
License (as archived): solo-consultazione
Archived: 2026-11-01T00:37:45.735Z
SHA-256 of the archived text: 07690e540aaee55409d80a000de07040276225cec27947d0b90bec93e18434f8
Stable URL of this page: https://metraipolis.com/documento/dc_8d12e048d1ea

How to cite

Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis:… — Europe PMC PMID:41973991 — Europe PMC (en), https://europepmc.org/article/MED/41973991 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8d12e048d1ea (Metraipolis archive dc_8d12e048d1ea, sha256 07690e540aaee55409d80a000de07040276225cec27947d0b90bec93e18434f8)

BibTeX

@misc{dc8d12e048d1ea,
  title = {Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis:… — Europe PMC PMID:41973991},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41973991},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8d12e048d1ea; sha256 07690e540aaee55409d80a000de07040276225cec27947d0b90bec93e18434f8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41973991. Agents can read the archived copy with the MCP tool read_document.